A$2.5 million just flowed into psychosocial risk software: what the round actually signals

In mid-September, workplace psychological safety platform ReFresh announced an A$2.5 million seed round led by Black Nova Venture Capital, with Antler and Archangel Ventures returning from its pre-seed. The raise takes the company's total funding past A$4 million, and the timing was not incidental: it landed two weeks before People at Work, the federally-backed survey around 5,000 Australian organisations and 160,000 workers have used to assess psychosocial risk since 2020, goes offline on 2 October. The investment thesis, as put by Black Nova managing partner and Donesafe co-founder Matt Browne, is worth reading closely regardless of which platform an organisation ultimately chooses. "A physical hazard has a location and a date, but psychosocial risk is the workload, the roster and the manager. Bolt a survey onto an incident register and you get a number at one end, a record at the other, and nothing in between." The critique is not of surveys as a measurement tool, it is of treating a once-a-year score as if it were a management system. That is a useful, independently-arrived-at confirmation of what regulator guidance has been saying since psychosocial hazards were written into WHS regulation: a survey identifies where risk sits, it does not control it, review it, or produce the evidence an inspector asks for. Capital moving into this category, from investors with no reason to align with any particular regulator's messaging, is a signal that the gap between "we measured the risk" and "we can show what we did about it" is now recognised as a real, fundable market problem, not a compliance nicety. For organisations weighing what to do as People at Work winds down, the practical takeaway sits above any single vendor's feature list. The question worth asking of any replacement is not whether it runs a survey, most will. It is whether it produces a record any PCBU actually owns: a named hazard, a named control, a named owner, and a review date, sitting in one place, ready to be shown rather than reconstructed under time pressure. That evidence chain, not the survey step in isolation, is what regulators have consistently asked to see, and what the current wave of investment into this category confirms the market has decided matters most.